A mathematical model describing drug uptake into brain tumors, directly from blood and indirectly from neighboring tissue, is presented. The model quantita tively describes uptake into tumor, brain surrounding tu mor (BST), and normal brain and uptake following re versible osmotic blood-brain barrier (BBB) and blood tumor barrier disruption. It employs published data on the time course for reclosure of the BBB following os motic treatment and on the brain and tumor uptake of [14Cju-aminoisobutyric acid by Walker 256 carcinomas and C6 gliomas implanted into the rat brain. Constant infusion and bolus injection infusion schedules are con-
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brain tumors (see, e.g., Neuwelt et al., 1980) . Al though many studies have shown greatly enhanced BBB permeability in normal brain, the effect of os motic treatment on the permeability of the BTB may be more moderate (Hiesiger et al., 1986) , par ticularly in those tumors with normally high BTB permeabilities. Furthermore, some chemotherapeu tic agents are also toxic to normal brain cells (N eu welt et al., 1983; Rapoport, 1988) , so that it is de sirable to limit exposure of normal brain to such substances while at the same time maximizing ex posure of the tumor cells. Therefore, it would be important to know the extent to which the advan tage of increasing drug entry into a brain tumor by the osmotic procedure is outweighed by exposing surrounding normal brain to higher levels of drug.
The answer to this question depends on several factors. First, the relative toxicities of the drug to tumor cells, normal brain cells, and cells in the rest of the body need to be taken into account. By os motic treatment, it is possible to expose tumor cells to the same total amount of drug at a lower total dose, allowing less exposure of cells in the rest of the body (except brain). Normal brain, on the other hand, may be more exposed because of the rela-tively greater enhancement of BBB than BTB per meability. With this possibility in mind, Neuwelt et aI. (1983) established a drug-screening procedure in animals and concluded that doxorubicin (Adriamy cin), cis-platinum, bleomycin, 5-fluorouracil, and mitomycin-C are too neurotoxic, when combined with the osmotic procedure, to be used clinically. On the other hand, cyclophosphamide and meth otrexate (MTX) were found to be not markedly neu rotoxic.
Exposure of tumor and normal brain to drug also depends on the infusion schedule of the drug, for example whether the drug is administered at a con stant rate or as a rapid bolus. The permeability of the BBB influences not only the rate of entry of the drug into the brain, but also its rate of return to the bloodstream after the bolus has passed.
The time course of BBB permeability following osmotic opening has been studied extensively in ex perimental animals for solutes of widely varying molecular sizes (Rapoport et aI., 1980; Ziylan et aI., 1983 Ziylan et aI., , 1984 Armstrong et aI., 1987) . For a particular drug, time-dependent BBB permeabilities in normal brain and tumor, together with a time-dependent plasma concentration of drug, lead to complex up take characteristics.
Finally, because of the spatial inhomogeneity of BBB permeability in the untreated brain with a brain tumor, and following osmotic treatment, con centration gradients of drug will be set up within the brain. In the untreated brain, a higher concentration of drug in the tumor than in the surrounding brain (due to a higher BTB than BBB permeability) es tablishes a concentration gradient from tumor to brain along which the drug may diffuse ("sink" ef fect) (Walker and Weiss, 1975; Rapoport, 1988) . There also may be bulk fluid flow between tumor and brain associated with peritumoral edema (Reu len et aI., 1988) . The net result of bulk flow and diffusion is to rapidly reduce drug concentrations at the proliferating edge of the tumor to levels consid erably lower than at the center.
The gradient might be reduced or reversed by enhancing BBB permeability even beyond the per meability of the BTB, thereby supplementing drug entry into the tumor from plasma ("source" effect). (Bulk fluid flow from plasma into brain following osmotic treatment may also enhance drug entry into the tumor; see Discussion.) This effect would be most apparent at the proliferating edge of the tu mor, particularly when the surrounding brain has considerably enhanced entry of drug compared to the tumor (i.e., the "worst" case for therapy with a potentially toxic agent).
To determine the relative contributions of differ- Vol. 10, No. 2, 1990 ences in permeability, gradients of concentration, and bulk flow to exposures of tumor and normal brain to drug, with and without osmotic treatment, and to assess the chemotherapeutic efficacy of this treatment, we developed a quantitative model for drug uptake into tumors and normal brain and for exchange between these regions. The model explicitly incorporates diffusion of drug within and between tumor and brain, before and following osmotic treatment. In the latter case, published time-dependent vascular permeabilities are used. The model is applied to published data on the uptake of AIB, a nonmetabolized amino acid that has a low rate of penetration across the intact BBB, by two kinds of tumor: C6 glioma, which has a fairly high vascular permeability (-10-20 times normal cortex), and Walker 256 carcinoma, which normally has a lower permeability (though still 3-6 times normal cortex) (Hiesiger et aI., 1986) . Diffu sion in brain tissue is a complex process, dependent on the size, shape, and charge of the diffusing sub stance and on the nature of the medium through which the diffusion takes place. In our initial model, we assume simple diffusion characterized by a sin gle diffusion coefficient. Entry into brain is also de pendent on the infusion schedule. Although any time-dependent infusion schedule can be used in the model, we study explicitly two extreme schedules: constant infusions and bolus injections.
THE MODEL
Consider a spherically symmetric tumor embed ded in brain tissue as shown in Fig. 1 . (A spherically symmetric tumor more accurately reflects the shape of tumors in animal models than in the clinical sit uation; however, the tumor shape is not critical for the general results that follow.) Let the tumor have a radius Rl and be surrounded by a region of peri tumoral brain tissue [brain surrounding tumor (BST)] to a distance R2 from the center of the tumor. BST in turn is surrounded by normal "distant" brain. Because spherical symmetry is as sumed, we describe the tumor, BST, and normal brain in spherical polar coordinates, with r repre senting the distance from the center of the tumor.
Let a drug or tracer that has been injected intra venously enter the arterial circulation of the brain with a time-dependent concentration in brain capil laries equal to CpI(t). Units of CpI(t) are, for example, millimoles per milliliter (or disintegrations per mil liliter for tracer). Assume that CpI(t) is the same in tumor, BST, and normal brain and does not depend on the distance r from the center of the tumor. Let tumor (r < R1), brain surrounding tumor (BST; R1 < r < R 2 ), and normal brain (r > R 2 )' For computational purposes, tu mor, BST, and brain are subdivided into volume elements (shells) by concentric spheres a distance I:!.r apart. ci repre sents concentration of drug in the ith shell from the center of the tumor. c(r,t) equal drug concentration at time t in a region at a distance r from the center of the tumor. c(r, t) is made up of two components: drug that has crossed the BBB (or BTB) directly from the plasma into the region and drug that has crossed the BBB (or BTB) elsewhere and diffused along a concentration gradi ent into the region.
The drug concentration at a particular point at a certain time depends on three factors: (a) The plasma concentration-time profile Cpl(t) of the drug up to the time of interest. (b) The unidirectional transfer coefficients kin and k out (s -I ) for the drug across the BBB (or BTB) from blood to brain and from brain to blood, respectively. kin and k out will in general depend on the distance r of the region from the center of the tumor. If the BBB is altered re versibly by osmotic treatment, then kin and k out will also depend on time: kin = kin(r,t) and k out = k out (r,t). The concentration of drug in brain (or tu mor), c(r,t), will therefore depend on the history of kin(r,t) and k out (r,t) up to the time of interest. (c) The diffusion coefficient D (cm 2 s -I ) for the drug in the brain and tumor tissue.
Apart from heterogeneities associated with the tumor itself, we assume that the brain tissue is ho mogeneous with respect to properties such as BBB permeability. We will ignore bulk flow across the BBB or BTB or within the brain tissue (except in sofar as it contributes to a measured effective per meability) (see Robinson and Rapoport, 1987) .
The explicit solution for c(r,t) is obtained by solv ing the equation of continuity in spherical coordi nates under appropriate initial and boundary condi tions, i.e.,
? ar ar '
(1)
where 1](r,t) is the source/sink term due to (a) move ment of drug across the BBB (or BTB) from plasma and (b) metabolism or irreversible binding of drug in the brain or brain tumor:
where kme t (s -I ) is the rate constant for metabolism or irreversible binding of the drug in brain. In what follows, we assume kin = k out = k (i.e., the BBB and BTB behave like passive barriers with the same permeability to the drug in either direction). Fur thermore, we assume for simplicity that the drug is not significantly metabolized in brain, so kmet = O. Equation 2 then simplifies to
Substituting for 1](r,t) from Eq. 3 into Eq. 1 gives
BBB permeability following osmotic opening (4)
BBB permeability for water-soluble compounds increases markedly following osmotic opening, de pending on molecular size (Rapoport et aI., 1980; Ziylan et aI., 1983 Ziylan et aI., , 1984 Armstrong et aI., 1987 ) and on molecular charge. For sucrose (molecular weight 340 daltons, molecular radius 5 A), the normal BBB has a unidirectional transfer coefficient k of -10 -5 s -1 (Ziylan et aI., 1983) . This increases to -2.5 x 10 -4 S -1 between 1 and 6 min after osmotic treat ment in most brain regions (and includes a bulk flow term) (Ziylan et aI., 1983) . As the barrier recloses, k falls to -1 x 10 -4 S -1 between 30 and 35 min and to -0.6 x 10-4 S -I by 5�55 min (Ziylan et aI., 1983) . The BBB recloses more rapidly for larger than for smaller compounds (Ziylan et aI., 1983 (Ziylan et aI., , 1984 Armstrong et aI., 1987; Robinson, 1987) .
To model BBB permeability changes to neutral water-soluble compounds following osmotic treat ment, we assume a time-dependent transfer coeffi cient of the following form:
where ko is the transfer coefficient for the intact (untreated) barrier and ko + kl is the value imme diately following osmotic treatment (at t = 0). Note that as the BBB recloses, k(t) approaches ko again (as t � 00) . u is the time constant for BBB reclosure following osmotic opening: k(t) has returned half way to its normal value by the time tllz = In 2/u. For sucrose, approximate values are ko = 10 -5 S -I and ko + kl = 2.5 X 10-4 s -I . BBB permeability has returned halfway to normal by �20 min following osmotic opening (Ziylan et aI., 1983) , so IX = In 21t1/2 = 0.035 min -I .
Numerical computations
Equation 4 may be solved numerically for c(r,t) by letting the tumor and surrounding brain be di vided by M concentric spheres a distance !!.r apart into a series of concentric volume elements or shells (see Fig. 1 ). Certain approximations then can be made. The first term on the right-hand side of Eq. 4 can be rewritten as (6) Now consider the ith concentric shell from the cen ter of the tumor, which has (mean) radius ri of (il/2)!!.r. The gradient of concentration across this shell can be approximated by
The second derivative a 2 c1ar can be approximated by the change in the gradient aclar across the ith shell as follows:
ar ar I1r (8) Substituting for aclar and a 2 c1ar from Eqs. 7 and 8 into Eq. 6, with ri = (i -Y2)l1r, and substituting the resulting expression for (lIr)alar (raclar) into Eq. 4 gives, as a numerical approximation for the time change of the concentration Ci in the ith concentric shell,
Note the dependence of ac/at on the concentrations in the neighboring shells C i + I and C i -I ' Because of spherical symmetry, we impose the boundary condition that the gradient of concentra tion at the center of the tumor is zero, i.e., C I = C2' Furthermore, at large distances from the tumor, we J Cereb Blood Flow Metab, Vol. 10, No. 2, 1990 also assume a zero concentration gradient, i.e.,
CM -I
Although the model allows the unidirectional transfer coefficient k to vary with distance from the center of the tumor, estimates of the magnitude of k from experiments are available only for three re gions: the tumor itself, BST, and normal brain some distance from the tumor. We therefore simplify the numerical computations by assuming only three re gions, each of which is homogeneous with respect to a regional k value (see Fig. 1 ), denoted by kT'
kBST' and kB' respectively, Equation 9 is therefore replaced with
where the concentric shells 1, ... , Ml are within the tumor, the next group of shells M 1 + 1, . . . , M2 are in BST, and the remaining shells M2 + 1, ... , M are in normal brain.
RESULTS
Equations 10 may be used to investigate the pen etration of drugs into tumor, BST, and normal brain, directly from plasma and indirectly by ex change with neighboring brain region(s). In un treated brain, the transfer coefficients kT' kBST' and kB are constant. Following osmotic treatment, these coefficients may increase to an extent depending on the characteristics of the drug and tumor of interest.
Each has a characteristic time dependence as the barrier recloses described by Eq. 5.
We illustrate how the model can be applied to conditions in which differential permeabilities of brain, BST, and tumor are like those determined from studies on the uptake of AIB by either Walker 256 carcinoma or C6 glioma implanted into rat brain. (AIB may be taken up into cells and bound; it is thus a good marker for regional permeability de terminations. However, in our simulation we as sume zero binding, which may more closely ap proximate the behavior of many drugs.) Values for kT, kBST, and kB in untreated brains and over 15 min following carotid infusion of 1.6 M mannitol in sa line are given in Table 1 (Hiesiger et aI., 1986) . We consider two extreme drug administration sched ules: constant intravenous infusion and bolus intra venous injection. We assume that AIB has a diffu sion coefficient D in brain of 10 -6 cm 2 s -I , slightly less than the free diffusion coefficient for sucrose in water of 5 x 10-6 cm 2 S-I (Lanman et aI., 1971) . Figure 2 illustrates solutions of Eqs. 10 for the Walker 256 carcinoma in the untreated brain with an intact BBB, with kT, kBST' and kB given (by ko) in Table 1 , for continuous infusion (Fig. 2a ) and bolus inputs (Fig. 2b). [The "bolus input" is taken as an instantaneous rise in concentration, followed by a monoexponential decay with a time constant of 1 min -I, approximating observed plasma curves fol lowing intravenous bolus injections; see Ziylan et al. (1983) .] The solid lines are calculated concentra tion profiles of AIB as a function of distance r from the center of the tumor at 5, 30, and 60 min after the onset of the constant infusion or the bolus injection. Broken lines show the profiles at these times in the absence of AIB diffusion within the tissues. In all cases, smooth profiles are interpolated between M = 14 points. Tumors are assumed to have a radius of 2 mm, giving them cross-sectional areas and vol umes close to those measured by Hiesiger et ai. (1986) for Walker 246 carcinomas.
When the BBB and BTB are opened osmotically, the (average) values of kT' kBST' and kB measured during the first 15 min following osmotic treatment are given as k(15) in Table 1 . If we assume that the time dependence of the k's is given by Eq. 5 above, then ko equals the value of k in the untreated tumor, BST, or brain, and the values of kl can be calculated from When T = 15 min, Eq. 11 becomes, on integration (with a = 0.035 min -I ) ,
Calculated values for kl also are given in Table 1 . Calculated concentration profiles for AIB in Walker 256 carcinoma are shown in Fig. 3 for continuous infusion (Fig. 3a ) and a bolus input (Fig. 3b) at 5, 30, and 60 min following osmotic opening. Profiles in the absence of diffusion in brain tissue are shown as broken lines. Total exposure of brain and tumor tissue to AIB is proportional to the time integral of the concen tration in the region of interest. For the ith concen tric shell, exposure to time T ex: JOT C i dt (13) Figure 4 shows AlB exposures between 0 and 60 min as a function of distance r from the center of the tumor for both constant infusion ( Fig. 4a ) and bolus injection (Fig. 4b) , with an intact BBB (lower curves) and following osmotic opening (upper curves). Again, broken lines show predicted expo sure profiles in the absence of diffusion within the tissues (D = 0). Figure 5 shows corresponding ex posure profiles predicted for a different tumor-a C6 glioma-whose permeability characteristics also are given in Table 1 . Data are means ± SEM (excepting k 1 ), expressed as s -1 X 10 3 , and from Hiesiger et al. (1986) . Table 1 ), are given in the text. BST, brain surrounding tumor. outside edge of the tumor is reduced by 21 % during a 1-h constant infusion (see Fig. 4a ). The reduction is even greater (28%) for a bolus injection (Fig. 4b ).
DISCUSSION
For the C6 glioma (Fig. 5 ), corresponding reduc tions in 1-h exposures are 24% (constant infusion) and 30% (bolus injection). For most tumors it is at the proliferating edge, where tumor cells frequently have high mitotic activity (Greig, 1987) , that it is important to maintain high concentrations of drug (Walker and Weiss, 1975) . Indeed, even moderate depletion of drug at the proliferating tumor edge due to a sink effect may determine whether treatment will be successful or not.
Following osmotic BBB opening, both tumor and brain become more permeable to AlB (Table 1) .
However, the brain shows a greater permeability increase, so that its vascular permeability exceeds that of tumor for some time following osmotic treat ment. (We assume that tumor and normal brain per meabilities follow a similar time course following osmotic opening; see The Model. This assumption might be later examined.) A reversal in relative per meabilities, and of the consequent concentration gradient, by osmotic treatment makes the brain an additional important source of AlB for the tumor (see Fig. 3a and b) . During a constant infusion of AlB, the integrated 1-h exposure following osmotic treatment 100 fLm in from the outer edge of a Walker 256 carcinoma is increased 31% by the ef fect of diffusion from surrounding brain (Fig. 4a) .
For a bolus injection, this exposure is increased by almost 44% (Fig. 4b ).
If we call the ratio of exposure to AlB following osmotic opening to exposure without osmotic treat ment the "enhancement factor" "I, then in the nor mal brain, "I for AlB at 1 h following osmotic open ing is 16-37 (constant infusion) and 17-30 (bolus),
whereas at the center of the tumor, "I equals 4.8 (constant infusion) and 5.6 (bolus) in the Walker 256 carcinoma and 1.3 (constant infusion) and 1.4 (bo lus) in the initially leakier C6 glioma (see Table 2 ).
Such relatively large enhancement factors in normal brain compared to tumor may not be desirable for a neurotoxic drug and have led to some reconsidera tion of the efficacy of the osmotic method for en hancing drug entry into brain tumors for chemother apeutic purposes (Fishman, 1987 (Fishman, , 1988 Groothuis and Blasberg, 1988; Shapiro, 1988; Shapiro et aI., 1988) . Indeed, it has been suggested that it may be an advantage to allow the BBB (and BTB) to remain intact, so that the brain can protect itself from such toxic drugs, while the tumors, which often have only partially intact barrier systems, are exposed to a relatively greater extent to the drug (Shapiro et aI., 1988) . This is, however, an oversimplification of a Defined as ratio of integrated exposure to drug following osmotic treatment to exposure without osmotic treatment. a complex situation, and a number of factors need to be taken into account before a realistic assess ment of the osmotic method can be made:
1. Before the osmotic method can be used to en hance drug entry into brain tumors and surrounding brain, a rigorous program of drug toxicity screening should be employed, as is done by N euwelt and co-workers (1983) , with the neurotoxicity of each specific drug evaluated in conjunction with osmotic treatment (Neuwelt and Barnett, 1989) .
2. There are considerable variations in vascular permeability between different types of brain tu mors. For example, in ethylnitrosourea-induced oli godendritic gliomas in rats, there is little disruption of the BTB compared to normal cortex (Blasberg et aI., 1983) , whereas in other tumor models in rats, such as virus-induced avian sarcoma and RG-2 and H-54 gliomas, the transfer constant k for AlB may be 15-30 times that for normal cortex (Blasberg and Groothuis, 1986) . There are also variations in k within many tumors (see Greig, 1989 ). In addition, it appears that permeability changes may take place during the growth of a tumor. Greig et al. (1983) , in a study of Walker 256 carcinomas in rats, demon strated that a small, growing tumor lesion had an intact BTB. Then, as the tumors grew, the integrity of the BTB became reduced, beginning in a local ized central area within the tumor and increasing both in magnitude and in area. In humans, local permeabilities can be measured in vivo using posi tron emission tomography (Kessler et aI., 1984) .
3. As discussed above, diffusion from surround ing brain to tumor following osmotic treatment (rather than in the reverse direction, as in the un treated case) enhances the integrated exposure of the outer edge of the tumor to drug. The extent of enhancement will depend on the type of tumor, the permeability characteristics to the drug, the drug administration regimen, and the diffusion coeffi-cient of the drug in brain and tumor tissue. For example, within the outer 100 J..L m of the Walker 256 carcinoma, the I-h enhancement factor "y for a con tinuous infusion of AlB is 6.2, whereas for the C6 glioma "y is 1.7 (compared with 4.8 and 1.3 at the centers of the respective tumors; see Table 2 ). In the BST just outside the tumor, a similar result is seen: for the Walker 256 carcinoma"y = 9.9, while for the C6 glioma"y = 2.9 ( Table 2) . 4. Osmotic opening of the BBB and BTB reduces the administered dose of drug necessary to achieve therapeutic effect against the tumor. Although ex posure of normal brain is enhanced (often by a fac tor greater than that of the tumor), exposure of pe ripheral organs to the toxic effects of the drug is reduced. An additional approach to increase drug delivery to CNS tumors and to minimize systemic concentration and toxicity is to administer chemo therapeutic agents intraarterially (Neuwelt and Bar nett, 1989) . AlB leads to a greater integrated exposure of nor mal brain than of tumor over I h (Fig. 4a, upper curve), whereas a bolus injection gives equivalent exposures (Fig. 4b, upper curve) . The reason for this is that while AlB diffuses into brain more readily than into tumor following osmotic treat ment, it also diffuses back out from brain more eas ily once the bolus has passed. In this case, there fore, the bolus injection helps to optimize tumor exposure relative to normal brain exposure to AlB.
In addition, the I-h enhancement factors "y for tu mor center, tumor edge, and BST following osmotic treatment are higher following a bolus injection than a continuous infusion (Table 2) It should be noted that a rapidly changing con centration-time profile C p l(t), such as a bolus, may be altered ("spread out" ) by passage through the microcirculation because, for example, of distribu tions of flow velocity within the vessels (Poiseuille flow). Differences in C p l(t) within tumor and normal brain, due to differences in microcirculation, may J Cereb Blood Flow Metab, Vol. 10, No. 2, 1990 then arise, but are beyond the sc,?pe of the present article.
Studies have been done on the entry of the water soluble anticancer agent MTX into implanted C6 gliomas in rats and into surrounding brain (Shapiro et aI., 1988) . These results indicated that prior to osmotic treatment, transfer coefficients ko for MTX into tumor, BST, and normal brain were 0.58 x 10-4 ,0 .28 X 10-4 , and 0.22 x 10-4 S-I, respec tively (Shapiro et aI., 1988, Thus, it appears that MTX normally enters the C6 glioma at a slower rate than AlB, although it enters normal brain at approximately the same rate. As suming similar diffusion rates in brain tissue, the sink effect would be greater for MTX than for AlB, leading to greater reductions in MTX exposure at the periphery of such tumors. Osmotic treatment would enhance the calculated integrated exposure of tumor, BST, and normal brain following a 2-min arterial injection of MTX by "y values of 2.8, 4.2, and 10.2, respectively, over a 90-min period (Sha piro et aI., 1988, Table 2 ). These enhancement fac tors are greater for the tumor, but less for normal brain, than those calculated for AlB (Table 2) . Os motic treatment would therefore be more effective in enhancing entry of MTX into the tumor than AlB, although the source effect, supplementing en try into tumor from surrounding tissue, would be smaller.
Studies on the size dependence of uptake follow ing BBB opening have suggested that bulk fluid flow from blood to brain contributes to enhanced permeability within 55 min of the hyperosmotic in fusion (Ziylan et aI., 1984; Robinson and Rapoport, 1987) . Bulk flow has been confirmed by indepen dent studies of the increase in brain water content of 1-1.5% within 10 min of barrier opening (Rapo port et aI., 1980). If bulk flow from blood to brain tissue is higher in regions of higher BBB permeabil ity in normal brain compared to most tumors, then the resulting hydrostatic pressure gradients be tween normal brain and tumor after osmotic treat ment could carry drugs into tumors from surround ing brain tissue by bulk connective flow. This pro cess may greatly supplement transport of drug to the tumor by diffusion from neighboring brain re gions, thus further enhancing the chemotherapeutic effectiveness of the osmotic method.
